By Colin Kellaher
Aclaris Therapeutics shares crumbled nearly 90% and hit an all-time low after the clinical-stage biopharmaceutical company threw in the towel on its most advanced program.
Shares of the Wayne, Pa., company were down 87% on Monday to 60.7 cents after touching an all-time low of 59 cents earlier in the session.
The…
Master your money.
Subscribe to MarketWatch.
Get this article and all of MarketWatch.
Access from any device. Anywhere. Anytime.
Subscribe Now
Already a subscriber?
Log In
Read the full article here
